ClinicalTrials.gg
Not yet recruitingNCT07266519SIRIUSUpdated Nov 19, 2026

SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

A Phase 2 interventional study of Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg and Sotatercept in Pulmonary Arterial Hypertension (PAH), sponsored by Philipps University Marburg. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Philipps University Marburg · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Planned enrollment
14th of 18
25 · median 44
Started
2026
with 3 others
Phase 2
7 of 18
3 open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Philipps University Marburg

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 14th largest by planned enrollment, is one of 4 that started in 2026, is one of 7 in phase 2, and was the 15th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The study aims to see how 24 weeks of triple therapy-an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept-affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension (PAH). SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up. It will enroll 25 patients and will be conducted only in countries where all treatments are available and covered. After 24 weeks, PAH treatment is decided by the doctor.

03

Conditions studied

  • Pulmonary Arterial Hypertension (PAH)

Keywords

  • triple therapy
  • PAH
  • treatment-naiive
04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-70 years
  2. Treatment-naïve patients diagnosed within 12 weeks prior to screening with I/H/D-PAH or PAH associated with corrected congenital heart disease (≥12 months after correction), irrespective of their WHO functional class at baseline.
  3. Patients who have been treated with ERA/PDE5i are eligible if treatment started after RHC which is not older than six weeks.
  4. PVR >5 WU, mPAP ≥35 mmHg and PAWP or LVEDP ≤15 mmHg at PAH diagnosis.
  5. Signed written
  6. For women of : A negative result in highly sensitive pregnancy test and willingness of additional monthly pregnancy testing during the duration of the trial and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Sotatercept is achieved after 112 days after the last administration of Sotatercept.
  7. For women of childbearing potential (WOCBP): a highly effective method of preferably with low user dependency, that has been in use for at least eight weeks prior inclusion in the study and continued during treatment and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Sotatercept is achieved 112 days after the last administration of Sotatercept.

    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation :

      • oral
      • intravaginal
      • transdermal
    • progestogen-only hormonal contraception associated with inhibition of ovulation:

      • oral
      • injectable
      • implantable
    • intrauterine device (IUD)
    • intrauterine hormone-releasing system (IUS)
    • bilateral tubal occlusion
    • vasectomised partner
    • sexual abstinence In addition to all contraception methods for WOCBP a condom must be used by the partner for contraception throughout the whole study.
  8. Willingness of males who are sexually active with a female partner of childbearing potential to use a condom. In addition, contraception of the female partner during treatment and until the end of relevant systemic exposure in WOCBP. End of relevant systemic exposure for the IMP Sotatercept is achieved after 112 days after the last administration of Sotatercept.

Exclusion criteria

Exclusion criteria

  1. Other forms of PH or PAH (patients with other forms of PAH are excluded because no sufficient safety and efficacy data exist for the treatment with sotatercept or -in the case of patients with CTD-associated PAH- the risk-benefit profile of sotatercept has not been sufficiently established).
  2. Use of PAH medications for more than 6 weeks prior to screening.
  3. PAH diagnosis more than 3 months prior to screening
  4. Symptoms or signs of lung disease, including TLC \<70%, /FVC \<60%, and DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide) \<45%, respectively.
  5. Signs of left heart failure with reduced or preserved , including LVEF \<50%, LAVI >34 ml/m2, E/é ≥15, or permanent atrial fibrillation, respectively.
  6. \<8 g/dL or >17 g/dL for women and >19g/dL for men at screening
  7. count \<80.000/µl at screening
  8. High bleeding risk by the discretion of the investigator
  9. Ongoing therapy with prostacyclin analogues or prostacyclin receptor agonists
  10. \<30 ml/min/m2 at screening
  11. Pregnancy or breastfeeding
  12. to the active substances or to any of the other
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Single arm

    Treatment arm

    Drug: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg · Drug: Sotatercept

Interventions

  • DrugSotatercept 0.3 mg/kg escalating to 0.7 mg/kg

    Drug page: SotaterceptStudies of SotaterceptSotatercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    subcutaneously administration in 3-weekly intervals

  • Patients are traitment-naiive before start of study. Therapy will be a triple combination therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and Sotatercept

06

What researchers measure

Primary outcomes

  1. Evaluation of the feasibility of recruitment, safety and treatment compliance of 24 weeks of triple combination therapy with an ERA, a PDE5i, and Sotatercept on pulmonary vascular resistance (PVR) in patients with newly diagnosed PAH.

    Trial feasibility evaluated at week 24 by recruitment rate, treatment compliance rate, and safety and tolerability rate.

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Oct 2028, 22 months later.

Of 52 phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 22 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 5, 2025
StartEst.
Dec 1, 2026was Jul 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Dec 1, 2026
Nov 19, 2026
Eligibility
4 inclusion criteria edited, 5 added, 9 removed; 3 exclusion criteria edited, 6 added, 3 removed
What changed in the criteria
Inclusion criteria
  • EditedTreatment-naïve patients diagnosed within 12 weeks prior to screening with I/H/D-PAH or PAH associated with corrected congenital heart disease (disease (≥12 months after correction). Patients who have received treatment with PDE5is and/or ERAs for up to 6 weeks after diagnosis are eligible provided that state-of-the-art right heart catheterization has been performed, irrespective of their WHO functional class at PAH diagnosisbaseline.
  • AddedPatients who have been treated with ERA/PDE5i are eligible if treatment started after RHC which is not older than six weeks.
  • RemovedNormal blood counts for platelets and erythrocytes
  • RemovedWomen of childbearing potential must be willing to remain abstinent or use adequate and reliable contraception throughout the study and for at least 4 months after the last dose of study medication has been received.
  • RemovedWOCBP must use one of the following highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly - according to recommendations by the European Heads of Medicines Agencies - from at least 14 days before the first administration of study medication until 4 month after the last administration of study medication:
  • AddedFor women of childbearing potential: A negative result in highly sensitive pregnancy test and willingness of additional monthly pregnancy testing during the duration of the trial and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Sotatercept is achieved after 112 days after the last administration of Sotatercept.
  • AddedFor women of childbearing potential (WOCBP): a highly effective method of contraception preferably with low user dependency, that has been in use for at least eight weeks prior inclusion in the study and continued during treatment and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Sotatercept is achieved 112 days after the last administration of Sotatercept.
  • Editedcombined (estrogen and progestogen containing) hor-monalhormonal contraception associated with inhibition of ovulation :
  • Editedprogestogen-only hormonal contraception associatedwithassociated with inhibition of ovulation:
  • Editedvasectomizedvasectomised partner
  • Removedsexual abstinence
  • RemovedMale participants with female partner(s) of childbearing potential are eligible to participate in the study if they agree to the following during treatment and until 304 daysmonths after the last administration of study medication:
  • RemovedInform any and all partner(s) of their participation in a clinical drug study and the need to comply with contraception instructions as directed by the investigator.
  • RemovedMale participants are required to use a condom during treatment and until 30 days4 months after the last administration of study medication.
  • RemovedFemale partners of male participants who have not undergone a vasectomy with the absence of sperm confirmed or a bilateral orchiectomy should consider use of effective methods of contraception during treatment and until 30 days4 months after the last administration of study medication.
  • RemovedSperm donation is not allowed during treatment and until 4 months after the last administration of study medication.
  • Addedsexual abstinence In addition to all contraception methods for WOCBP a condom must be used by the partner for contraception throughout the whole study.
  • AddedWillingness of males who are sexually active with a female partner of childbearing potential to use a condom. In addition, contraception of the female partner during treatment and until the end of relevant systemic exposure in WOCBP. End of relevant systemic exposure for the IMP Sotatercept is achieved after 112 days after the last administration of Sotatercept.
Exclusion criteria
  • RemovedOther Forms of PH or PAH
  • AddedOther forms of PH or PAH (patients with other forms of PAH are excluded because no sufficient safety and efficacy data exist for the treatment with sotatercept or -in the case of patients with CTD-associated PAH- the risk-benefit profile of sotatercept has not been sufficiently established).
  • AddedPAH diagnosis more than 3 months prior to screening
  • EditedSymptoms or signs of clinically relevant lung disease, including TLC < 70%, FEV1/FVC <60%, and DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide) <45%, respectively.
  • RemovedHistory of severe bleeding/haemorrhage
  • RemovedTherapy with prostacyclin and/or antithrombotic agents
  • AddedHemoglobin <8 g/dL or >17 g/dL for women and >19g/dL for men at screening
  • AddedThrombocyte count <80.000/µl at screening
  • AddedHigh bleeding risk by the discretion of the investigator
  • AddedOngoing therapy with prostacyclin analogues or prostacyclin receptor agonists
  • EditedeGFR <30 ml/min/m2. at screening
  • EditedHypersensitivity to the active substancesubstances or to any of the other excipients
Nov 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Assessment of the effect on pulmonary vascular resistance (PVR)Now Evaluation of the feasibility of recruitment, safety and treatment compliance of 24 weeks of triple combination therapy with an ERA, a PDE5i, and Sotatercept on pulmonary vascular resistance (PVR) in patients with newly diagnosed PAH.Time frame: 24 weeks
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Jul 1, 2026→Dec 1, 2026
    Eligibility 4 inclusion criteria edited, 5 added, 9 removed; 3 exclusion criteria edited, 6 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • EditedTreatment-naïve patients diagnosed within 12 weeks prior to screening with I/H/D-PAH or PAH associated with corrected congenital heart disease (disease (≥12 months after correction). Patients who have received treatment with PDE5is and/or ERAs for up to 6 weeks after diagnosis are eligible provided that state-of-the-art right heart catheterization has been performed, irrespective of their WHO functional class at PAH diagnosisbaseline.
    • AddedPatients who have been treated with ERA/PDE5i are eligible if treatment started after RHC which is not older than six weeks.
    • RemovedNormal blood counts for platelets and erythrocytes
    • RemovedWomen of childbearing potential must be willing to remain abstinent or use adequate and reliable contraception throughout the study and for at least 4 months after the last dose of study medication has been received.
    • RemovedWOCBP must use one of the following highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly - according to recommendations by the European Heads of Medicines Agencies - from at least 14 days before the first administration of study medication until 4 month after the last administration of study medication:
    • AddedFor women of childbearing potential: A negative result in highly sensitive pregnancy test and willingness of additional monthly pregnancy testing during the duration of the trial and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Sotatercept is achieved after 112 days after the last administration of Sotatercept.
    • AddedFor women of childbearing potential (WOCBP): a highly effective method of contraception preferably with low user dependency, that has been in use for at least eight weeks prior inclusion in the study and continued during treatment and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Sotatercept is achieved 112 days after the last administration of Sotatercept.
    • Editedcombined (estrogen and progestogen containing) hor-monalhormonal contraception associated with inhibition of ovulation :
    • Editedprogestogen-only hormonal contraception associatedwithassociated with inhibition of ovulation:
    • Editedvasectomizedvasectomised partner
    • Removedsexual abstinence
    • RemovedMale participants with female partner(s) of childbearing potential are eligible to participate in the study if they agree to the following during treatment and until 304 daysmonths after the last administration of study medication:
    • RemovedInform any and all partner(s) of their participation in a clinical drug study and the need to comply with contraception instructions as directed by the investigator.
    • RemovedMale participants are required to use a condom during treatment and until 30 days4 months after the last administration of study medication.
    • RemovedFemale partners of male participants who have not undergone a vasectomy with the absence of sperm confirmed or a bilateral orchiectomy should consider use of effective methods of contraception during treatment and until 30 days4 months after the last administration of study medication.
    • RemovedSperm donation is not allowed during treatment and until 4 months after the last administration of study medication.
    • Addedsexual abstinence In addition to all contraception methods for WOCBP a condom must be used by the partner for contraception throughout the whole study.
    • AddedWillingness of males who are sexually active with a female partner of childbearing potential to use a condom. In addition, contraception of the female partner during treatment and until the end of relevant systemic exposure in WOCBP. End of relevant systemic exposure for the IMP Sotatercept is achieved after 112 days after the last administration of Sotatercept.
    Exclusion criteria
    • RemovedOther Forms of PH or PAH
    • AddedOther forms of PH or PAH (patients with other forms of PAH are excluded because no sufficient safety and efficacy data exist for the treatment with sotatercept or -in the case of patients with CTD-associated PAH- the risk-benefit profile of sotatercept has not been sufficiently established).
    • AddedPAH diagnosis more than 3 months prior to screening
    • EditedSymptoms or signs of clinically relevant lung disease, including TLC < 70%, FEV1/FVC <60%, and DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide) <45%, respectively.
    • RemovedHistory of severe bleeding/haemorrhage
    • RemovedTherapy with prostacyclin and/or antithrombotic agents
    • AddedHemoglobin <8 g/dL or >17 g/dL for women and >19g/dL for men at screening
    • AddedThrombocyte count <80.000/µl at screening
    • AddedHigh bleeding risk by the discretion of the investigator
    • AddedOngoing therapy with prostacyclin analogues or prostacyclin receptor agonists
    • EditedeGFR <30 ml/min/m2. at screening
    • EditedHypersensitivity to the active substancesubstances or to any of the other excipients
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Assessment of the effect on pulmonary vascular resistance (PVR)Now Evaluation of the feasibility of recruitment, safety and treatment compliance of 24 weeks of triple combination therapy with an ERA, a PDE5i, and Sotatercept on pulmonary vascular resistance (PVR) in patients with newly diagnosed PAH.Time frame: 24 weeks
    + 1 other change: design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07266519
Collaborators
MSD Sharp & Dohme GmbH, Germany
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

SIRIUS Study Team
Contact
sirius@kks.uni-marburg.de
+4915114980915
Karen Olsson, Prof. Dr.
principal investigator · Hannover Medical School Department of Respiratory Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion